Last reviewed · How we verify

BRENTUXIMAB VEDOTIN — Competitive Intelligence Brief

BRENTUXIMAB VEDOTIN (BRENTUXIMAB VEDOTIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD30-directed Immunoconjugate [EPC].

marketed CD30-directed Immunoconjugate [EPC] Antibody drug conjugate Live · refreshed every 30 min

Target snapshot

BRENTUXIMAB VEDOTIN (BRENTUXIMAB VEDOTIN).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BRENTUXIMAB VEDOTIN TARGET BRENTUXIMAB VEDOTIN marketed CD30-directed Immunoconjugate [EPC] 2011-01-01
Adcetris brentuximab-vedotin Pfizer marketed CD30-directed Immunoconjugate [EPC] Tubulin beta 2011-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD30-directed Immunoconjugate [EPC] class)

  1. · 1 drug in this class
  2. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BRENTUXIMAB VEDOTIN — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1742994. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: